Mounjaro (tirzepatide) has become one of the most talked-about medicines in UK weight management, and most of that conversation centres on results. Far less of it centres on what the medicine actually does to the body along the way, which is arguably the more useful thing to understand before you start. Tirzepatide is a dual GIP and GLP-1 receptor agonist given as a once-weekly subcutaneous injection, made by Eli Lilly, and like any medicine that changes how the gut and appetite signalling work, it comes with a predictable set of effects.
The point of an article like this is not to put anyone off. Most people who take tirzepatide under proper supervision experience side effects that are mild to moderate, cluster in the early weeks, and settle. But a small number of effects are serious enough that recognising them early genuinely matters, and there are groups of people for whom the medicine is not appropriate at all. Knowing which is which is the difference between managing a rough fortnight sensibly and missing something that needs urgent attention.
In the UK, Mounjaro is a prescription-only medicine. It cannot legally be supplied without a consultation with a prescriber, who assesses your medical history, current medicines and suitability before anything is dispensed. That consultation is not a formality to be got through — it is the mechanism by which most of the risks described below are screened for in advance.
Why the gastrointestinal effects come first
The most common side effects of tirzepatide are gastrointestinal: nausea, diarrhoea, vomiting, constipation, reduced appetite and general abdominal discomfort. These are listed as common in the product information, and they are the effects most people will actually encounter.
They are not random in their timing. They tend to be at their most noticeable in the first few weeks of treatment and again in the days following each dose increase, then ease as the body adjusts. This pattern is a direct consequence of how the medicine works — it slows gastric emptying and alters appetite and satiety signalling, and the digestive system takes time to settle at each new level of exposure.
Understanding that pattern helps. It makes an uncomfortable first fortnight less alarming, because it is expected rather than a sign that something has gone wrong, and it explains why the week after a dose step-up is worth planning around.
Why prescribers titrate slowly
The standard approach with tirzepatide is to begin at 2.5 mg weekly for four weeks — a starting dose intended to let the body acclimatise, not a treatment dose — and then step up in 2.5 mg increments no sooner than every four weeks, through 5, 7.5, 10 and 12.5 mg, to a maximum of 15 mg weekly.
That deliberate pace exists largely because of tolerability. Moving up quickly tends to produce sharper gastrointestinal effects, and a person who feels persistently unwell is more likely to stop treatment altogether. Prescribers will also frequently hold someone at a lower dose if it is working and well tolerated, rather than climbing towards the maximum as a default. The highest dose is a ceiling, not a target.
None of this is something to adjust independently. Dose decisions belong with the prescriber who knows your history, and the patient information leaflet supplied with the pen is the authoritative source for how yours should be used.
Less common effects worth knowing about
Beyond the gastrointestinal cluster, several other effects are reported less frequently but often enough to be worth recognising.
- Injection-site reactions — redness, itching or a small lump where the pen was used. Usually mild and short-lived; rotating injection sites is standard practice and is covered in the leaflet.
- Fatigue — some people feel noticeably more tired, particularly early on. Reduced food intake can contribute, which is one reason eating adequately matters even when appetite is low.
- Dizziness — sometimes related to reduced intake or fluid loss, sometimes to low blood sugar in people also taking certain diabetes medicines.
- Hair thinning — reported by some people during significant weight loss. It is worth raising with a prescriber rather than assuming nothing can be done.
Low blood sugar and other medicines
Tirzepatide on its own carries a relatively low risk of hypoglycaemia, but that risk rises meaningfully when it is combined with insulin or a sulfonylurea. This is one of the clearest reasons a full medicines list must be disclosed at consultation: a prescriber may need to consider whether existing diabetes treatment requires adjustment, and that is not a decision to be made without them.
Symptoms of low blood sugar — shakiness, sweating, confusion, unusual hunger, dizziness — should be treated as usual and reported to whoever manages your diabetes care.
Uncommon but serious: what to act on
A small number of effects are uncommon but serious. They are not reasons to expect the worst; they are reasons to know what a warning sign looks like rather than waiting it out.
Pancreatitis. Severe, persistent abdominal pain — often in the upper abdomen, sometimes radiating to the back, frequently with vomiting — is the signal here. This is not the same as ordinary early nausea. Severe or persistent abdominal pain of this kind warrants urgent medical assessment; do not wait for the next scheduled appointment.
Gallbladder problems. Rapid weight loss is associated with gallstones generally, and gallbladder problems are recognised with this class of medicine. Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools should prompt medical advice without delay, and urgent care if pain is severe or accompanied by fever or jaundice.
Dehydration and kidney injury. Persistent vomiting or diarrhoea can cause dehydration, and dehydration can in turn lead to acute kidney injury. If you cannot keep fluids down, are passing very little urine, or feel severely lightheaded, that needs same-day medical advice rather than another day of hoping it passes.
For any of these, the appropriate route is your GP, NHS 111, or A&E if symptoms are severe. It is also worth noting that anyone looking at where to buy mounjaro in the UK will find that a registered pharmacy requires a clinical consultation and a prescriber’s review before supply, and gives patients a route back for exactly these situations.
Who Mounjaro is not suitable for
Some contraindications are absolute, and screening for them is a core function of the consultation.
- Pregnancy and breastfeeding — tirzepatide is not suitable during either. Anyone planning a pregnancy should discuss this with their prescriber well in advance.
- Personal or family history of medullary thyroid carcinoma, or MEN2 (multiple endocrine neoplasia syndrome type 2) — treatment is not appropriate.
- History of pancreatitis — requires caution and a considered clinical decision.
- Severe gastrointestinal disease — requires caution, given the effect on gastric emptying.
- Diabetic retinopathy — requires caution and appropriate monitoring.
This is also why the eligibility criteria for supply exist. UK services generally require an adult aged 18 or over with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as type 2 diabetes, hypertension or dyslipidaemia, where lifestyle change alone has not been sufficient. A regulated provider such as Cured Pharmacy applies those criteria through an online clinical assessment reviewed by a prescriber, and a declined application is the system working rather than failing.
MHRA advice on oral contraceptives
This is a safety point that is easy to miss and has real consequences. The MHRA has advised that people using oral contraceptives should use an additional barrier method — or switch to a non-oral form of contraception — for four weeks after starting tirzepatide, and for four weeks after each dose increase.
The reason is the same delayed gastric emptying that causes the gastrointestinal effects: it can reduce absorption of the oral contraceptive and therefore its reliability. Because the four-week window resets at every dose step, someone titrating upwards may be covering several separate periods across their first months of treatment, not just one at the beginning.
Effects at a glance
EffectHow commonWhat to doNausea, vomiting, diarrhoea, constipation, reduced appetite, abdominal discomfortCommonUsually worst early and after dose increases; follow the leaflet, keep fluids up, tell your prescriber if it is not settlingInjection-site reactionsLess commonUsually mild; mention to your pharmacist or prescriber if persistent or spreadingFatigue, dizzinessLess commonCheck intake and hydration; raise with your prescriber, especially if you also take insulin or a sulfonylureaHair thinningLess commonNot urgent, but worth discussing at reviewLow blood sugarHigher risk with insulin or a sulfonylureaTreat as advised for hypoglycaemia and contact whoever manages your diabetes careSevere, persistent abdominal pain (possible pancreatitis)Uncommon, seriousSeek urgent medical care — GP same day, NHS 111, or A&E if severeGallbladder symptoms (upper right pain, fever, jaundice)Uncommon, seriousSeek prompt medical advice; urgent care if severe or with fever or jaundiceDehydration or reduced urine output after prolonged vomitingUncommon, seriousSeek same-day medical advice — risk of acute kidney injury
Interactions and history to disclose
A consultation is only as good as the information it is given. The items worth volunteering, even if they feel irrelevant, include:
- All current medicines, including insulin and sulfonylureas, and any other diabetes treatment.
- Oral contraceptives, given the MHRA advice above.
- Any medicine where timing or absorption matters to you, since gastric emptying is slowed.
- Over-the-counter medicines and supplements, which people routinely forget to mention.
- Any history of pancreatitis, gallbladder disease, thyroid cancer or MEN2, kidney problems, eating disorders, or significant gastrointestinal disease.
- Pregnancy, plans for pregnancy, or breastfeeding.
Muscle mass, protein and why treatment is not the whole plan
Weight lost during treatment is not exclusively fat. Some loss of lean tissue accompanies substantial weight reduction, and appetite suppression can make it easy to fall short of adequate protein without noticing.
This is one of the clearest reasons tirzepatide is used alongside diet, physical activity and ongoing support rather than instead of them. Resistance exercise and sufficient protein intake are the standard means of protecting muscle mass during weight loss, and a prescriber or dietitian can advise on what is appropriate for an individual. Eating adequately, even with reduced appetite, is part of using the medicine well.
What happens when treatment stops
Tirzepatide works while it is being taken. When it is stopped, the appetite and satiety effects fade, and appetite generally returns towards where it was before. Weight regain is a well-recognised pattern after stopping treatment of this kind.
That is worth thinking about before starting rather than afterwards. Stopping is sometimes necessary — because of side effects, cost, pregnancy plans or a change in circumstances — and it is a decision to make with a prescriber, alongside a plan for what follows.
Reporting side effects: the Yellow Card scheme
The MHRA runs the Yellow Card scheme for reporting suspected side effects of medicines in the UK. Patients and carers can report directly, not only healthcare professionals, and reports contribute to ongoing safety monitoring of medicines in real-world use.
Reporting is not a substitute for seeking medical help. If something is worrying you now, contact your GP, pharmacist, prescriber or NHS 111 — then report separately.
A word on where the medicine comes from
Every safety point above assumes a legitimate product supplied through a regulated route. The MHRA has repeatedly warned about counterfeit weight-loss pens sold through social media and unregistered websites, where there is no reliable way to know what the device contains.
A UK online pharmacy should be checkable on the GPhC register at pharmacyregulation.org.uk, both the pharmacy and its superintendent pharmacist, and should display its registered premises number and the distance-selling logo. Any seller that does not require a genuine consultation, or that offers to skip the prescriber, should be avoided outright.
Frequently asked questions
How long do the early side effects usually last?
Gastrointestinal effects are typically most noticeable in the first weeks and in the days after each dose increase, and commonly settle as the body adjusts. If they are severe, or not improving, that is a reason to contact your prescriber rather than to push through.
Do I need to use extra contraception?
If you use oral contraceptives, MHRA advice is to use an additional barrier method or a non-oral method for four weeks after starting tirzepatide and for four weeks after each dose increase, because delayed gastric emptying can reduce absorption. Discuss your options with your prescriber or pharmacist.
Can I get Mounjaro on the NHS?
NICE technology appraisal TA1026 recommends tirzepatide for managing overweight and obesity, but NHS England is running a phased rollout. In primary care the initial phase is limited to people with a BMI of 35 or more, adjusted for ethnicity, plus four weight-related conditions from dyslipidaemia, hypertension, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Specialist weight management services may use different criteria, and local ICBs decide implementation — your GP or ICB can tell you what applies where you live.
Is nausea a sign I should stop?
Not on its own — mild to moderate nausea is common early and after dose increases. Severe or persistent abdominal pain, an inability to keep fluids down, or symptoms suggesting gallbladder problems are different, and those warrant prompt or urgent medical assessment. Any decision to stop or change a dose should be made with your prescriber.
Taking the safety side seriously
Tirzepatide has a predictable side effect profile, most of which is manageable and time-limited. The parts that need attention are the ones that are easy to talk yourself out of acting on: pain that is worse than discomfort, vomiting that will not stop, symptoms that do not fit the expected pattern. Knowing those in advance is most of what preparation involves.
The rest is the ordinary work of using any long-term medicine well — an honest consultation, a full medicines list, reading the patient information leaflet that comes with the pen, eating and moving in a way that supports the treatment, and staying in contact with the prescriber rather than managing alone.
This article is general information only and is not medical advice. It is not a recommendation to take any particular medicine or dose. Mounjaro is a prescription-only medicine in the UK and can only be supplied following a consultation with a prescriber. Always speak to your GP, pharmacist or prescriber about your own circumstances, and read the patient information leaflet supplied with your medicine.
